Allergan PLC ALLERGAN ORD SHS/  IE00BY9D5467  /

London International
5/20/2019  4:18:05 PM Chg. -0.50 Volume Bid5/17/2018 Ask- Market Capitalization Dividend Y. P/E Ratio
139.61USD -0.36% 570
Turnover: 79,526.43
-Bid Size: - -Ask Size: - 45.96 bill.USD 2.05% -

Business description

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model -- Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world. Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.
 

Management board & Supervisory board

CEO
Brenton L. Saunders
Management board
Matt Walsh, Alex Kelly, Bill Meury, Bob Bailey, Dr. C. David Nicholson, Karen Ling, Wayne R. Swanton
Supervisory board
Brenton L. Saunders, Adriane M. Brown, Carol Anthony (John) Davidson, Catherine M. Klema, Christopher J. Coughlin, Christopher W. Bodine, Joseph H. Boccuzi, Michael E. Greenberg, Nesli Basgoz, Peter J. McDonnell, Robert J. Hugin, Thomas C. Freyman
 

Company data

Name: Allergan plc
Address: 1 Grand Canal Square, Docklands,Dublin 2, Ireland
Phone: +1-862-261-7000
Fax: -
E-mail: -
Internet: www.allergan.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 78.79%
IPO date: -

Investor relations

Name: Daphne Karydas
IR phone: +1-862-261-8006
IR-Fax: -
IR e-mail: -

Company calendar

CW 24 | 6/14/2019 Dividend Payment
 

Main Shareholders

Freefloat
 
78.79%
Wellington Management Group LLP
 
7.49%
The Vanguard Group
 
7.27%
BlackRock, Inc.
 
6.45%